USANA Health Sciences (USNA) Projected to Release Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is expected to post its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.11 per share and revenue of $217.42 million for the quarter. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Individuals can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 11:00 AM ET.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). The firm had revenue of $223.27 million for the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. On average, analysts expect USANA Health Sciences to post $0.76 EPS for the current fiscal year and $1.77 EPS for the next fiscal year.

USANA Health Sciences Trading Down 0.3%

NYSE USNA opened at $14.27 on Monday. The firm has a market capitalization of $263.71 million, a price-to-earnings ratio of -11.79, a P/E/G ratio of 1.57 and a beta of 0.66. USANA Health Sciences has a 1 year low of $12.57 and a 1 year high of $23.59. The firm’s 50 day simple moving average is $14.55 and its 200 day simple moving average is $18.13.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, September 21st. Zacks Research raised USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. Finally, Wall Street Zen lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, USANA Health Sciences currently has an average rating of “Reduce”.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.